Main Industry
Biotechnology
Main Product/Service
1. HANSIZHUANG (serplulimab)
2. HLX04 (bevacizumab)
3. HLX10 (serplulimab, HANSIZHUANG)
4. HLX53
5. Manufacturing and Quality Management
6. Clinical Trials
2. HLX04 (bevacizumab)
3. HLX10 (serplulimab, HANSIZHUANG)
4. HLX53
5. Manufacturing and Quality Management
6. Clinical Trials
Founded Year
2010
Unified Business No.
53183491
Status
Closed
Number of Employees
0
Total Paid-in
Capital
780,511,490 (NT$)
Location of Company
Taiwan
, Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Shanghai Henlius Biotech provides clinical-stage biopharmaceutical services. The company focuses on the development, production and commercialization of mAb biosimilar drugs, bio-betters, and novel mAbs using cutting-edge technology.
The company is a joi
The company is a joi